Candyce Kroenke to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Candyce Kroenke has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
1.860
-
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast?cancer. J Natl Cancer Inst. 2026 Jul 01; 118(7):1278-1289.
Score: 0.231
-
The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer. Cancer. 2026 Mar 15; 132(6):e70318.
Score: 0.226
-
Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer. Cancer. 2026 Mar 01; 132(5):e70294.
Score: 0.225
-
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer. J Natl Cancer Inst. 2026 Feb 01; 118(2):307-315.
Score: 0.224
-
Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancer. Breast Cancer Res Treat. 2025 Aug; 213(1):115-126.
Score: 0.216
-
Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study. JCO Clin Cancer Inform. 2025 Feb; 9:e2400231.
Score: 0.210
-
The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system. Breast Cancer Res Treat. 2024 Nov; 208(2):405-414.
Score: 0.203
-
Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019. Breast Cancer Res. 2024 Jun 13; 26(1):101.
Score: 0.200
-
Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study. Cancer. 2017 Dec 15; 123(24):4868-4877.
Score: 0.125